Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 178

1.

Analysis of HIV-1 matrix-envelope cytoplasmic tail interactions.

Alfadhli A, Staubus AO, Tedbury PR, Novikova M, Freed EO, Barklis E.

J Virol. 2019 Aug 2. pii: JVI.01079-19. doi: 10.1128/JVI.01079-19. [Epub ahead of print]

PMID:
31375589
2.

The autophagy protein ATG9A promotes HIV-1 infectivity.

Mailler E, Waheed AA, Park SY, Gershlick DC, Freed EO, Bonifacino JS.

Retrovirology. 2019 Jul 3;16(1):18. doi: 10.1186/s12977-019-0480-3.

3.

Heavy metal protease takes a tiki torch to HIV assembly.

O'Doherty U, Freed EO.

Nat Immunol. 2019 Jun;20(6):668-669. doi: 10.1038/s41590-019-0387-0. No abstract available.

PMID:
31061529
4.

Multiple Roles of HIV-1 Capsid during the Virus Replication Cycle.

Novikova M, Zhang Y, Freed EO, Peng K.

Virol Sin. 2019 Apr;34(2):119-134. doi: 10.1007/s12250-019-00095-3. Epub 2019 Apr 26. Review.

5.

Mutations in the HIV-1 envelope glycoprotein can broadly rescue blocks at multiple steps in the virus replication cycle.

Van Duyne R, Kuo LS, Pham P, Fujii K, Freed EO.

Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9040-9049. doi: 10.1073/pnas.1820333116. Epub 2019 Apr 11.

PMID:
30975760
6.

TIM-mediated inhibition of HIV-1 release is antagonized by Nef but potentiated by SERINC proteins.

Li M, Waheed AA, Yu J, Zeng C, Chen HY, Zheng YM, Feizpour A, Reinhard BM, Gummuluru S, Lin S, Freed EO, Liu SL.

Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5705-5714. doi: 10.1073/pnas.1819475116. Epub 2019 Mar 6.

PMID:
30842281
7.

Resistance to Second-Generation HIV-1 Maturation Inhibitors.

Urano E, Timilsina U, Kaplan JA, Ablan S, Ghimire D, Pham P, Kuruppu N, Mandt R, Durell SR, Nitz TJ, Martin DE, Wild CT, Gaur R, Freed EO.

J Virol. 2019 Mar 5;93(6). pii: e02017-18. doi: 10.1128/JVI.02017-18. Print 2019 Mar 15.

PMID:
30567982
8.

Myosin-X is essential to the intercellular spread of HIV-1 Nef through tunneling nanotubes.

Uhl J, Gujarathi S, Waheed AA, Gordon A, Freed EO, Gousset K.

J Cell Commun Signal. 2019 Jun;13(2):209-224. doi: 10.1007/s12079-018-0493-z. Epub 2018 Nov 15.

9.

Meeting Review: 2018 International Workshop on Structure and Function of the Lentiviral gp41 Cytoplasmic Tail.

Fernandez MV, Freed EO.

Viruses. 2018 Nov 7;10(11). pii: E613. doi: 10.3390/v10110613.

10.

Identification of a Structural Element in HIV-1 Gag Required for Virus Particle Assembly and Maturation.

Novikova M, Adams LJ, Fontana J, Gres AT, Balasubramaniam M, Winkler DC, Kudchodkar SB, Soheilian F, Sarafianos SG, Steven AC, Freed EO.

MBio. 2018 Oct 16;9(5). pii: e01567-18. doi: 10.1128/mBio.01567-18.

11.

HIV-1 packs in PACSIN2 for cell-to-cell spread.

Van Duyne R, Freed EO.

Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):6885-6887. doi: 10.1073/pnas.1808821115. Epub 2018 Jun 20. No abstract available.

12.

Single molecule fate of HIV-1 envelope reveals late-stage viral lattice incorporation.

Buttler CA, Pezeshkian N, Fernandez MV, Aaron J, Norman S, Freed EO, van Engelenburg SB.

Nat Commun. 2018 May 10;9(1):1861. doi: 10.1038/s41467-018-04220-w.

13.

High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release.

Waheed AA, Gitzen A, Swiderski M, Freed EO.

Viruses. 2018 Jan 5;10(1). pii: E26. doi: 10.3390/v10010026.

14.

Quenching protein dynamics interferes with HIV capsid maturation.

Wang M, Quinn CM, Perilla JR, Zhang H, Shirra R Jr, Hou G, Byeon IJ, Suiter CL, Ablan S, Urano E, Nitz TJ, Aiken C, Freed EO, Zhang P, Schulten K, Gronenborn AM, Polenova T.

Nat Commun. 2017 Nov 24;8(1):1779. doi: 10.1038/s41467-017-01856-y.

15.

Intracellular Reassociation of RNA-DNA Hybrids that Activates RNAi in HIV-Infected Cells.

Martins AN, Ke W, Jawahar V, Striplin M, Striplin C, Freed EO, Afonin KA.

Methods Mol Biol. 2017;1632:269-283. doi: 10.1007/978-1-4939-7138-1_18.

PMID:
28730446
16.

A Consensus View of ESCRT-Mediated Human Immunodeficiency Virus Type 1 Abscission.

Lippincott-Schwartz J, Freed EO, van Engelenburg SB.

Annu Rev Virol. 2017 Sep 29;4(1):309-325. doi: 10.1146/annurev-virology-101416-041840. Epub 2017 Jul 17. Review.

PMID:
28715971
17.

"Expand and Click": A New Method for Labeling HIV-1 Envelope Glycoproteins.

Fernandez MV, Freed EO.

Cell Chem Biol. 2017 May 18;24(5):548-550. doi: 10.1016/j.chembiol.2017.05.006.

18.

A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.

Urano E, Miyauchi K, Kojima Y, Hamatake M, Ablan SD, Fudo S, Freed EO, Hoshino T, Komano J.

ChemMedChem. 2016 Oct 19;11(20):2320-2326. doi: 10.1002/cmdc.201600375. Epub 2016 Sep 16.

PMID:
27634404
19.

Getting IN on Viral RNA Condensation and Virion Maturation.

Freed EO.

Cell. 2016 Aug 25;166(5):1082-1083. doi: 10.1016/j.cell.2016.08.013.

20.

Identification of potent maturation inhibitors against HIV-1 clade C.

Timilsina U, Ghimire D, Timalsina B, Nitz TJ, Wild CT, Freed EO, Gaur R.

Sci Rep. 2016 Jun 6;6:27403. doi: 10.1038/srep27403.

21.

The Vpu-interacting Protein SGTA Regulates Expression of a Non-glycosylated Tetherin Species.

Waheed AA, MacDonald S, Khan M, Mounts M, Swiderski M, Xu Y, Ye Y, Freed EO.

Sci Rep. 2016 Apr 22;6:24934. doi: 10.1038/srep24934.

22.

Trimer Enhancement Mutation Effects on HIV-1 Matrix Protein Binding Activities.

Alfadhli A, Mack A, Ritchie C, Cylinder I, Harper L, Tedbury PR, Freed EO, Barklis E.

J Virol. 2016 May 27;90(12):5657-5664. doi: 10.1128/JVI.00509-16. Print 2016 Jun 15.

23.

Structural and Molecular Determinants of Membrane Binding by the HIV-1 Matrix Protein.

Mercredi PY, Bucca N, Loeliger B, Gaines CR, Mehta M, Bhargava P, Tedbury PR, Charlier L, Floquet N, Muriaux D, Favard C, Sanders CR, Freed EO, Marchant J, Summers MF.

J Mol Biol. 2016 Apr 24;428(8):1637-55. doi: 10.1016/j.jmb.2016.03.005. Epub 2016 Mar 16.

24.

The Use of Minimal RNA Toeholds to Trigger the Activation of Multiple Functionalities.

Afonin KA, Viard M, Tedbury P, Bindewald E, Parlea L, Howington M, Valdman M, Johns-Boehme A, Brainerd C, Freed EO, Shapiro BA.

Nano Lett. 2016 Mar 9;16(3):1746-53. doi: 10.1021/acs.nanolett.5b04676. Epub 2016 Feb 29.

25.

Biochemical evidence of a role for matrix trimerization in HIV-1 envelope glycoprotein incorporation.

Tedbury PR, Novikova M, Ablan SD, Freed EO.

Proc Natl Acad Sci U S A. 2016 Jan 12;113(2):E182-90. doi: 10.1073/pnas.1516618113. Epub 2015 Dec 28.

26.

Identification of an HIV-1 Mutation in Spacer Peptide 1 That Stabilizes the Immature CA-SP1 Lattice.

Fontana J, Keller PW, Urano E, Ablan SD, Steven AC, Freed EO.

J Virol. 2015 Nov 4;90(2):972-8. doi: 10.1128/JVI.02204-15. Print 2016 Jan 15.

27.

Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain.

Martins AN, Waheed AA, Ablan SD, Huang W, Newton A, Petropoulos CJ, Brindeiro RD, Freed EO.

J Virol. 2015 Oct 28;90(2):768-79. doi: 10.1128/JVI.01640-15. Print 2016 Jan 15.

28.

Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.

Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP, Martin DE, Nitz TJ, Wild CT, Freed EO.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):190-7. doi: 10.1128/AAC.02121-15. Print 2016 Jan.

29.

IFITM Proteins Restrict HIV-1 Infection by Antagonizing the Envelope Glycoprotein.

Yu J, Li M, Wilkins J, Ding S, Swartz TH, Esposito AM, Zheng YM, Freed EO, Liang C, Chen BK, Liu SL.

Cell Rep. 2015 Oct 6;13(1):145-156. doi: 10.1016/j.celrep.2015.08.055. Epub 2015 Sep 17.

30.

HIV-1 assembly, release and maturation.

Freed EO.

Nat Rev Microbiol. 2015 Aug;13(8):484-96. doi: 10.1038/nrmicro3490. Epub 2015 Jun 29. Review.

PMID:
26119571
31.

NMR structure of the myristylated feline immunodeficiency virus matrix protein.

Brown LA, Cox C, Baptiste J, Summers H, Button R, Bahlow K, Spurrier V, Kyser J, Luttge BG, Kuo L, Freed EO, Summers MF.

Viruses. 2015 Apr 30;7(5):2210-29. doi: 10.3390/v7052210.

32.

Rab27a controls HIV-1 assembly by regulating plasma membrane levels of phosphatidylinositol 4,5-bisphosphate.

Gerber PP, Cabrini M, Jancic C, Paoletti L, Banchio C, von Bilderling C, Sigaut L, Pietrasanta LI, Duette G, Freed EO, Basile Gde S, Moita CF, Moita LF, Amigorena S, Benaroch P, Geffner J, Ostrowski M.

J Cell Biol. 2015 May 11;209(3):435-52. doi: 10.1083/jcb.201409082. Epub 2015 May 4.

33.

HIV-1 gag: an emerging target for antiretroviral therapy.

Tedbury PR, Freed EO.

Curr Top Microbiol Immunol. 2015;389:171-201. doi: 10.1007/82_2015_436. Review.

PMID:
25731773
34.

Announcing the 2015 viruses Young Investigator Prize and Graduate Student/Postdoctoral Fellow Travel awards.

Freed EO.

Viruses. 2015 Feb 12;7(2):707-8. doi: 10.3390/v7020707. No abstract available.

35.

Elucidating the mechanism by which compensatory mutations rescue an HIV-1 matrix mutant defective for gag membrane targeting and envelope glycoprotein incorporation.

Tedbury PR, Mercredi PY, Gaines CR, Summers MF, Freed EO.

J Mol Biol. 2015 Mar 27;427(6 Pt B):1413-1427. doi: 10.1016/j.jmb.2015.01.018. Epub 2015 Feb 7.

36.

The cytoplasmic tail of retroviral envelope glycoproteins.

Tedbury PR, Freed EO.

Prog Mol Biol Transl Sci. 2015;129:253-84. doi: 10.1016/bs.pmbts.2014.10.009. Epub 2014 Dec 1. Review.

PMID:
25595807
37.

In COS cells Vpu can both stabilize tetherin expression and counteract its antiviral activity.

Waheed AA, Kuruppu ND, Felton KL, D'Souza D, Freed EO.

PLoS One. 2014 Oct 31;9(10):e111628. doi: 10.1371/journal.pone.0111628. eCollection 2014.

38.

HIV-1 Vpu accessory protein induces caspase-mediated cleavage of IRF3 transcription factor.

Park SY, Waheed AA, Zhang ZR, Freed EO, Bonifacino JS.

J Biol Chem. 2014 Dec 19;289(51):35102-10. doi: 10.1074/jbc.M114.597062. Epub 2014 Oct 28.

39.

Multifunctional RNA nanoparticles.

Afonin KA, Viard M, Koyfman AY, Martins AN, Kasprzak WK, Panigaj M, Desai R, Santhanam A, Grabow WW, Jaeger L, Heldman E, Reiser J, Chiu W, Freed EO, Shapiro BA.

Nano Lett. 2014 Oct 8;14(10):5662-71. doi: 10.1021/nl502385k. Epub 2014 Sep 30.

40.

The ins and outs of viral infection: keystone meeting review.

Bird SW, Kirkegaard K, Agbandje-McKenna M, Freed EO.

Viruses. 2014 Sep 25;6(9):3652-62. doi: 10.3390/v6093652.

41.

TIM-family proteins inhibit HIV-1 release.

Li M, Ablan SD, Miao C, Zheng YM, Fuller MS, Rennert PD, Maury W, Johnson MC, Freed EO, Liu SL.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):E3699-707. doi: 10.1073/pnas.1404851111. Epub 2014 Aug 18.

42.

MicroRNA binding to the HIV-1 Gag protein inhibits Gag assembly and virus production.

Chen AK, Sengupta P, Waki K, Van Engelenburg SB, Ochiya T, Ablan SD, Freed EO, Lippincott-Schwartz J.

Proc Natl Acad Sci U S A. 2014 Jul 1;111(26):E2676-83. doi: 10.1073/pnas.1408037111. Epub 2014 Jun 17.

43.

The role of matrix in HIV-1 envelope glycoprotein incorporation.

Tedbury PR, Freed EO.

Trends Microbiol. 2014 Jul;22(7):372-8. doi: 10.1016/j.tim.2014.04.012. Epub 2014 Jun 2. Review.

44.

Antiviral innate immunity: editorial overview.

Freed EO, Gale M Jr.

J Mol Biol. 2014 Mar 20;426(6):1129-32. doi: 10.1016/j.jmb.2014.01.005. Epub 2014 Jan 22. No abstract available.

PMID:
24462565
45.

Distribution of ESCRT machinery at HIV assembly sites reveals virus scaffolding of ESCRT subunits.

Van Engelenburg SB, Shtengel G, Sengupta P, Waki K, Jarnik M, Ablan SD, Freed EO, Hess HF, Lippincott-Schwartz J.

Science. 2014 Feb 7;343(6171):653-6. doi: 10.1126/science.1247786. Epub 2014 Jan 16.

46.

Global rescue of defects in HIV-1 envelope glycoprotein incorporation: implications for matrix structure.

Tedbury PR, Ablan SD, Freed EO.

PLoS Pathog. 2013;9(11):e1003739. doi: 10.1371/journal.ppat.1003739. Epub 2013 Nov 14.

47.

Dual-acting stapled peptides target both HIV-1 entry and assembly.

Zhang H, Curreli F, Waheed AA, Mercredi PY, Mehta M, Bhargava P, Scacalossi D, Tong X, Lee S, Cooper A, Summers MF, Freed EO, Debnath AK.

Retrovirology. 2013 Nov 15;10:136. doi: 10.1186/1742-4690-10-136.

48.

A two-pronged structural analysis of retroviral maturation indicates that core formation proceeds by a disassembly-reassembly pathway rather than a displacive transition.

Keller PW, Huang RK, England MR, Waki K, Cheng N, Heymann JB, Craven RC, Freed EO, Steven AC.

J Virol. 2013 Dec;87(24):13655-64. doi: 10.1128/JVI.01408-13. Epub 2013 Oct 9.

49.

Activation of virus uptake through induction of macropinocytosis with a novel polymerizing peptide.

Daniels SI, Soule EE, Davidoff KS, Bernbaum JG, Hu D, Maeda K, Stahl SJ, Naiman NE, Waheed AA, Freed EO, Wingfield P, Yarchoan R, Davis DA.

FASEB J. 2014 Jan;28(1):106-16. doi: 10.1096/fj.13-238113. Epub 2013 Oct 4.

50.

Mutations in the feline immunodeficiency virus envelope glycoprotein confer resistance to a dominant-negative fragment of Tsg101 by enhancing infectivity and cell-to-cell virus transmission.

Luttge BG, Panchal P, Puri V, Checkley MA, Freed EO.

Biochim Biophys Acta. 2014 Apr;1838(4):1143-52. doi: 10.1016/j.bbamem.2013.08.020. Epub 2013 Sep 10.

Supplemental Content

Loading ...
Support Center